Anti-Human IFNA1 Recombinant Antibody (Sifalimumab) (CAT#: TAB-H62)

Add to basket Submit an inquiry form Compare

• Published Data
• Gene Expression
• Datasheet
• MSDS
• COA

ELISA

Figure 1 Pharmacokinetics (PK) and pharmacodynamics of sifalimumab over time in patients with systemic lupus erythematosus (PK population).

Serum concentrations of sifalimumab. Patients who missed the last 3 doses were excluded from the analysis.

Petri, M., Wallace, D. J., Spindler, A., Chindalore, V., Kalunian, K., Mysler, E., ... & Yao, Y. (2013). Sifalimumab, a human anti–interferon‐α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose‐escalation study. Arthritis & Rheumatism, 65(4), 1011-1021.

Inhib

Figure 2 Change from baseline in disease activity.

Combined sifalimumab group (n 121) and placebo group (n 40).

Petri, M., Wallace, D. J., Spindler, A., Chindalore, V., Kalunian, K., Mysler, E., ... & Yao, Y. (2013). Sifalimumab, a human anti–interferon‐α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose‐escalation study. Arthritis & Rheumatism, 65(4), 1011-1021.

RNA Expression

Figure 1 RNA cell line category: Cell line enhanced (HeLa, hTERT-RPE1)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000197919-IFNA1

Figure 1 RNA cell line category: Cell line enhanced (HeLa, hTERT-RPE1)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000197919-IFNA1

 Datasheet

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Specifications

Product Property

Applications

Target

Related Resources

Product Notes

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Sifalimumab"

Afuco™ Anti-IFNA1 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H62)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human IFNA1. It is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.

DrugMonitor™ Anti-Sifalimumab Antibody (VS-1224-YC1087)

Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha, potentially suppressing abnormal immune activity in lupus by binding to multiple interferon-alpha subtypes. The DrugMonitor™ Anti-Sifalimumab Antibody (VS-1224-YC1087) is an anti-drug antibody (ADA) against Sifalimumab. This drug-based antibody is raised in mice immunized with the Sifalimumab. The anti-Sifalimumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Sifalimumab in samples.

See other products for "IFNA1"

Customer Reviews and Q&As

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H62, RRID: AB_3112039)

Popular products with customers

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.